Skip to content
Buy This GLP
← Research
Evidence

GLP-1 Drugs and New-Onset Sleep Apnea: A UK Cohort of 47,315 Users

A UK cohort found no clear difference in new obstructive sleep apnea diagnoses between adults with obesity and type 2 diabetes starting GLP-1 drugs or DPP-4 inhibitors.

Editorial profile: Carla MedinaBuy This GLP Editorial Team4 min read
New sleep apnea diagnoses: GLP-1 vs DPP-4 inhibitors1.070.931.231.047,315 on a GLP-1 against 159,066 on the comparator, up to three years

What the UK cohort measured

Researchers used UK primary care records from 2007 to 2023. They identified 47,315 adults starting a GLP-1 receptor agonist and 159,066 starting a DPP-4 inhibitor. Everyone had type 2 diabetes and a BMI of at least 30 and had no prior recorded sleep apnea diagnosis. The researchers weighted the groups within BMI categories to balance measured baseline characteristics and used an as-treated analysis with up to three years of follow-up[1].

There were 612 new diagnoses in the GLP-1 group and 1,197 in the DPP-4 inhibitor group. The incidence rates were 5.8 and 5.4 per 1,000 person-years, respectively. The confidence interval around the hazard ratio of 1.07 included both a lower and a higher diagnosis rate. Results were consistent across BMI groups, sex, drug type and sensitivity analyses [1].

How this differs from the treatment trials

The SURMOUNT-OSA tirzepatide trials used sleep studies to measure breathing events among adults with obesity who already had moderate-to-severe obstructive sleep apnea. Tirzepatide reduced events compared with placebo in both trials [2]. The U.S. FDA indication is for Zepbound in adults with obesity and moderate-to-severe obstructive sleep apnea [3].

A clinical diagnosis in primary care can depend on who is referred and tested. It does not tell researchers exactly when apnea began. The survey of sleep-clinic follow-up practices covers a separate example of how follow-up can vary after treatment and weight loss. The UK cohort compared prescriptions in routine care, so it could not isolate the effect of weight loss itself.

Frequently asked

Do GLP-1 drugs prevent obstructive sleep apnea?
The UK cohort found no clear difference in new diagnoses between adults with obesity and type 2 diabetes starting a GLP-1 drug or a DPP-4 inhibitor. The hazard ratio was 1.07 (95% CI 0.93–1.23).
Can tirzepatide treat existing obstructive sleep apnea?
Yes. Randomized trials showed reduced apnea severity in adults with obesity and moderate-to-severe obstructive sleep apnea. The FDA approved Zepbound for this population.
Did everyone in the cohort get a sleep study?
The cohort used clinically recorded diagnoses. Researchers did not conduct standardized sleep studies for all participants, so the result can reflect differences in testing or referral.

Sources

  1. [1] Khouri C, et al. (2026). Effectiveness of GLP-1 receptor agonists to prevent obstructive sleep apnea in patients with type 2 diabetes: active comparator, new user cohort study American Journal of Respiratory and Critical Care Medicine. PMID 42745463
  2. [2] Malhotra A, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity New England Journal of Medicine. PMID 38912654
  3. [3] U.S. Food and Drug Administration (2026). Zepbound U.S. prescribing information FDA. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence